Ignite Creation Date:
2024-05-06 @ 1:40 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01864772
Status:
COMPLETED
Last Update Posted:
2022-08-19
First Post:
2013-05-21
Brief Title:
Phase II Trial of Carboplatin 5-FU and Cetuximab in Elderly Fit no Frailty Patients With RecurrentMetastatic HNSCC
Sponsor:
Groupe Oncologie Radiotherapie Tete et Cou
Organization:
Groupe Oncologie Radiotherapie Tete et Cou
Study Overview
Official Title:
Phase II Multicenter Trial Evaluating First Line Carboplatin 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Aged 70 and Over Ranked as Fit no Frailty by Geriatric Assessment
Status:
COMPLETED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ELANFIT
Brief Summary:
The aim of the trial is to evaluate the clinical benefit efficacy safety preservation of autonomy of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty after geriatric assessment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None